Recent News

• 05.27.2025 - Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes
• 05.14.2025 - Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results
• 04.30.2025 - Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025
• 04.24.2025 - NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD
• 04.11.2025 - Lucid Diagnostics Announces Closing of Public Offering of Common Stock

Recent Filings

• 05.23.2025 - 4/A Statement of changes in beneficial ownership of securities
• 05.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.22.2025 - S-3 Registration statement under Securities Act of 1933
• 05.14.2025 - EX-99.1 EX-99.1
• 05.14.2025 - 8-K Current report
• 05.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.30.2025 - DEF 14A Other definitive proxy statements
• 04.30.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.30.2025 - ARS Annual Report to Security Holders
• 04.25.2025 - 8-K Current report